23461 South Pointe Drive
20 articles with BioLargo, Inc.
BioLargo, Inc. (OTCQB:BLGO), a developer of sustainable technologies and full-service environmental engineering company, announced today that it will be giving an investor presentation at the upcoming LD Micro virtual event on Wednesday, June 9, 2021, at 5:00 PM ET.
BioLargo (BLGO) Q1 2021 Earnings Webcast and Conference Call Wednesday, May 19, 2021 - 4:30 PM Eastern Time
BioLargo, Inc., a developer of sustainable clean- technologies and full-service environmental engineering company, will host an investor webcast and conference call on Wednesday May 19, 2021, at 1:30 pm PT / 4:30 pm ET, open to the public.
BioLargo, Inc. (OTCQB:BLGO), developer of sustainable clean technologies and a full-service environmental engineering company will be presenting at the Benzinga Cleantech Small Cap Conference on Earth Day, April 22, 2021, at 11:20am EST.
BioLargo 2020 Annual Report Highlights Expanding Commercial Traction for its Cleantech Technologies, Record Revenue Growth and Improved Balance Sheet
BioLargo, Inc., a developer of sustainable cleantech technologies and full-service environmental engineering company, filed its Annual Report on Form 10-K with the SEC for the year ended December 31, 2020.
BioLargo, Inc. (OTCQB:BLGO), developer of sustainable technologies and a full-service environmental engineering company, filed with the SEC its Quarterly Report on Form 10-Q for the period ended September 30, 2020 ( www.biolargo.com/sec-filings ). BioLargos Third Quarter Accomplishments Record revenue - generated record revenues in the third quarter, rebounding from early pandemic shutdowns
BioLargo, Inc, announced today that its subsidiary BioLargo Engineering, Science & Technologies (BLEST) has been awarded a contract to assist in the reconfiguration of the Regenerative Thermal Oxidizer (RTO) systems used at a large chemical manufacturing plant on the East Coast of the US, owned by a global chemical company,
BioLargo Subsidiary Clyra Medical’s Clyraguard Product Shows Complete Inactivation of SARS-CoV-2 Virus in Galveston National Lab Study
BioLargo, Inc. announced that Clyraguard, the product developed by its partially owned subsidiary Clyra Medical Technologies in response to the COVID-19 pandemic has been successfully shown to cause complete inactivation of the SARS-CoV-2 virus in laboratory testing.
Dennis Calvert, CEO of BioLargo, Inc., Returns to Uptick Newswire’s Stock Day Podcast to Discuss the Company’s Record-Breaking Quarterly Results and a Progress Report on its March to its First Industry-Wide Adoption
Dennis Calvert, CEO of BioLargo, Inc. (OTCQB: BLGO) recently spoke with “Stock Day” host Everett Jolly about BioLargo’s progress since the previous show at the end of July.
BioLargo, Inc. Secures Financing For Its Advanced Wound Care Products Targeting FDA Application, Approval And Commercialization Through Its Subsidiary Clyra Medical Technologies
BioLargo, Inc. Achieves Breakout Milestones in Advanced Wound Care on Track for FDA 510(k) Submission and Commercialization
BioLargo, Inc. Adds Wound Management Expert and Former VP at Smith & Nephew Inc., Tanya Rhodes, to Its Team
BioLargo, Inc. Adds Water Expert and Former Pepsi-Cola International VP-Technical Services -- Harry DeLonge to Its Team
NuWay Medical, Inc. Changes Name to BioLargo, Inc.; Announces Reverse Stock Split, Recapitalization, and Conversion of Debt and Payables to Equity